Suppr超能文献

C反应蛋白水平在肝硬化患者中的预后价值。

Prognostic value of C-reactive protein levels in patients with cirrhosis.

作者信息

Di Martino Vincent, Coutris Caroline, Cervoni Jean-Paul, Dritsas Stavros, Weil Delphine, Richou Carine, Vanlemmens Claire, Thevenot Thierry

机构信息

Service d'Hépatologie et de Soins Intensifs Digestifs, Centre Hospitalier Régional Universitaire Hôpital Jean Minjoz, Besançon, France.

Université de Franche Comté, Unité de Formation et de Recherche des Sciences Médicales et Pharmaceutiques, Besançon, France.

出版信息

Liver Transpl. 2015 Jun;21(6):753-60. doi: 10.1002/lt.24088. Epub 2015 Apr 18.

Abstract

I dentifying cirrhosis with a poor short-term prognosis remains crucial for improving the allocation of liver grafts. The purpose of this study was to assess the prognostic value of a model combining the variation of C-reactive protein (CRP) levels within 15 days, the Model for End-Stage Liver Disease (MELD) score, and the presence of comorbidities in patients with decompensated cirrhosis with a Child-Pugh score > B7 and to test the relevance of this model in patients with compensated cirrhosis. We collected data for cirrhotic patients without hepatocellular carcinoma, extrahepatic malignancy, human immunodeficiency virus infection, organ transplantation, seen between January 2010 and December 2011. Multivariate analyses of predictors of 3-month mortality used Cox models adjusted with the age-adjusted Charlson comorbidity index. The prognostic performance [area under receiver operating characteristic curves (AUROCs)] of the 3-variable model was compared to that of the MELD score. The 241 patients who met the inclusion criteria included 109 patients with a Child-Pugh score > B7 who were hospitalized for decompensation. In these patients with severe cases, the 3-month mortality was independently predicted by the MELD score [hazard ratio (HR), 1.10; 95% confidence interval (CI), 1.05-1.14; P < 0.001] and a CRP level > 32 mg/L at the baseline and on day 15 (HR, 2.21; 95% CI, 1.03-4.76; P = 0.042). This model was better than MELD alone (AUROC, 0.789 versus 0.734; P = 0.043). In the whole population with cirrhosis, the 3-month mortality was also predicted by high MELD scores (HR, 1.11; 95% CI, 1.07-1.16; P < 0.001) and a CRP level > 10 mg/L at the baseline and on day 15 (HR, 2.89; 95% CI, 1.29-6.48; P < 0.001), but the AUROCs of the 3-variable model and the MELD score alone were no longer significantly different (0.89 versus 0.88, not significant). In conclusion, prognostic models incorporating variations in CRP predict 3-month mortality in patients with cirrhosis. Such models are particularly relevant for patients with decompensated cirrhosis but provide a limited increase in prediction in comparison with the MELD score in the whole population with cirrhosis.

摘要

识别短期预后较差的肝硬化对于改善肝移植分配至关重要。本研究的目的是评估一个模型的预后价值,该模型结合了15天内C反应蛋白(CRP)水平的变化、终末期肝病模型(MELD)评分以及Child-Pugh评分> B7的失代偿期肝硬化患者的合并症情况,并测试该模型在代偿期肝硬化患者中的相关性。我们收集了2010年1月至2011年12月期间就诊的无肝细胞癌、肝外恶性肿瘤、人类免疫缺陷病毒感染、器官移植的肝硬化患者的数据。使用经年龄调整的Charlson合并症指数调整的Cox模型对3个月死亡率的预测因素进行多变量分析。将三变量模型的预后性能[受试者操作特征曲线下面积(AUROCs)]与MELD评分的预后性能进行比较。符合纳入标准的241例患者包括109例因失代偿而住院的Child-Pugh评分> B7的患者。在这些重症患者中,3个月死亡率由MELD评分独立预测[风险比(HR),1.10;95%置信区间(CI),1.05 - 1.14;P < 0.001]以及基线和第15天时CRP水平> 32 mg/L(HR,2.21;95% CI,1.03 - 4.76;P = 0.042)。该模型优于单独的MELD评分(AUROC,0.789对0.734;P = 0.043)。在整个肝硬化患者群体中,3个月死亡率也由高MELD评分(HR,1.11;95% CI,1.07 - 1.16;P < 0.001)以及基线和第15天时CRP水平> 10 mg/L(HR,2.89;95% CI,1.29 - 6.48;P < 0.001)预测,但三变量模型和单独的MELD评分的AUROCs不再有显著差异(0.89对0.88,无显著性)。总之,纳入CRP变化的预后模型可预测肝硬化患者的3个月死亡率。此类模型对于失代偿期肝硬化患者尤为相关,但与整个肝硬化患者群体中的MELD评分相比,其预测能力的提升有限。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验